Skip to main content

Table 1 Patient and tumor characteristics

From: Second-line treatment of recurrent HNSCC: tumor debulking in combination with high-dose-rate brachytherapy and a simultaneous cetuximab-paclitaxel protocol

  

Total group (n = 94)

Study group (n = 18)

Control group (n = 18)

p-values*

  

n

%

value (range)

n

%

value (range)

n

%

value (range)

 
 

Age < 60 years

36

38.3

 

13

72.2

 

5

27.8

  
 

Age ≥ 60 years

58

61.7

 

5

27.8

 

13

72.2

  
 

Age at onset of recurrence disease (years)

  

62.0 (53–71)

  

48.0 (45–68)

  

66.5 (57–73)

(0.006)

 

Time to first recurrence < 3 months

10

10.3

 

9

50.0

 

0

0

  
 

Time to first recurrence ≥ 3 months

81

83.5

 

6

33.3

 

18

100

  
 

Previous recurrence free survival (months)

  

24.0 (10–73)

  

2.3 (2–8)

  

38.1 (18–99)

(0.003)

 

First recurrence

49

52.1

 

9

50.0

 

7

38.9

  
 

Several recurrences

45

47.9

 

9

50.0

 

11

61.1

  

Previous treatment

Operation

72

76.6

 

12

66.7

 

13

72.2

 

(0.177)

 

Chemotherapy

25

26.1

 

6

33.1

 

8

44.0

 

(0.978)

 

Radiotherapy

63

67.0

 

15

83.3

 

17

94.4

 

(0.584)

 

Previous total radiation dose (Gy)

  

64.2 (33–105)

  

68.1 (50–105)

  

66.2 (59–77)

(0.696)

rTNM-stage

T1-T2

38

40.4

 

5

27.8

 

7

38.9

 

(0.812)

 

T3-T4

45

47.9

 

10

55.6

 

9

50.0

  
 

Tx

9

9.6

 

3

16.7

 

2

11.1

  
 

N0

67

71.3

 

13

72.2

 

12

66.7

 

(1.000)

 

N1-N2

21

22.4

 

3

16.7

 

4

22.2

  
 

N3

3

3.2

 

2

11.1

 

1

5.6

  

UICC-stage

Stage I-II

31

33.0

 

6

33.3

 

5

27.8

 

(1.000)

 

Stage III-IV

63

67.0

 

12

66.7

 

13

72.2

  

Histology

SCC

75

79.8

 

17

94.4

 

15

83.3

 

(0.735)

 

Other

19

20.2

 

1

5.6

 

3

16.7

  

Grading

Low Grade (G1-G2)

50

53.2

 

12

66.7

 

7

38.9

 

(0.156)

 

High Grade (G3-G4)

41

43.6

 

6

33.3

 

11

61.1

  

Localization

Oral cavity

24

25.5

 

7

38.9

 

4

22.2

 

(0.308)

 

Oro-, nasopharynx

26

27.7

 

5

27.8

 

9

50.0

  
 

Hypopharynx, larynx

6

6.4

 

2

11.1

 

1

5.6

  
 

Lymph node

8

8.5

 

3

16.7

 

2

11.1

  
 

Other

30

31.9

 

1

5.6

 

2

11.1

  

Resection margins

R0

37

39.4

 

4

22.2

 

6

33.3

 

(0.766)

 

R1

32

34.0

 

10

55.6

 

5

27.8

  
 

R2

11

11.7

 

3

16.7

 

4

22.2

  
 

Rx (unsure)

6

6.4

 

1

5.6

 

-

-

  
 

No debulking

8

8.5

 

1

5.6

 

3

16.7

  

Tissue invasion

L0, V0, Pn0

26

27.7

 

3

16.7

 

2

11.1

 

(0.733)

 

L1, V1 or Pn1

20

21.3

 

5

27.8

 

7

38.9

  
 

No neck dissection

48

51.1

 

10

55.6

 

9

50,0

 

(1.000)

  1. Shows the patient and tumor characteristics for the total group, study group receiving the cetuximab-taxane schema and the matched pair control group that potentially influence prognosis. Differences between the study group and the control group were analyzed by *chi-square test and Mann–Whitney U test